Skip to main content

Table 4 Factors influencing health-related quality of life among hospitalized cancer cases in India

From: Health-related quality of life and its determinants among cancer patients: evidence from 12,148 patients of Indian database

Parameter

B

Std. Error

95% Confidence Interval

p-value*

Lower

Upper

(Intercept)

0.500

0.038

0.426

0.574

0.000

Age

-0.002

0.000

-0.003

-0.001

0.000

Hospital Days

-0.003

0.002

-0.006

0.000

0.060

Type of Hospital (Reference - Public)

Semi-private

0.231

0.016

0.200

0.263

0.000

Education (Refernce- No Education)

Primary & Middle

0.031

0.020

-0.009

0.071

0.133

Up to Senior Secondary

0.031

0.021

-0.009

0.072

0.128

 

Graduation & above

0.075

0.023

0.030

0.120

0.001

Type of Cancer (Reference-Solid)

Haematological

-0.033

0.027

-0.086

0.020

0.218

Type of Treatment (Reference- Chemotherapy)

Radiotherapy

-0.025

0.033

-0.090

0.039

0.440

Palliative care

-0.258

0.056

-0.367

-0.149

0.000

Surgery

-0.127

0.033

-0.192

-0.062

0.000

Combination Therapy**

-0.133

0.024

-0.181

-0.085

0.000

Maintenance Therapy

-0.702

0.151

-0.998

-0.406

0.000

On diagnostic workup

-0.144

0.037

-0.216

-0.072

0.000

Hormone Therapy

-0.163

0.184

-0.523

0.198

0.377

Immunotherapy

0.098

0.062

-0.022

0.219

0.110

Others (clinical follow up)

-0.136

0.029

-0.193

-0.080

0.000

Line of Treatment (Reference - First Line)

Second Line

-0.065

0.025

-0.114

-0.017

0.008

Third Line

0.037

0.062

-0.084

0.158

0.550

Fourth Line

0.117

0.104

-0.086

0.321

0.258

Response to Treatment (Reference– Disease free survival)

Progressive

-0.149

0.040

-0.227

-0.071

0.000

Ongoing

0.016

0.024

-0.031

0.064

0.504

Adverse Effect (Reference - With Adverse Effect)

Without Adverse Effect

0.085

0.025

0.037

0.133

0.001

  1. *Level of significance at p- value less than 0.05, **Combination therapy– Chemotherapy + Radiotherapy, Surgery + Radiotherapy, Surgery + Chemotherapy, Surgery + Chemotherapy + Radiotherapy. Ongoing treatment-response cannot be assessed among patients on active oncology treatment